18336-75-9

Basic information

• Product Name: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE
• Synonyms: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE
• CAS NO: 18336-75-9
• Molecular Formula: C₁₁H₁₁N₃O₂
• Molecular Weight: 217.22
• Mol File: 18336-75-9.mol

Chemical Properties

• Melting Point: 173-175°C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.244 g/cm³
• Refractive Index: 1.586
• PKA: 10.94±0.10(Predicted)
• CAS DataBase Reference: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE(18336-75-9)
• EPA Substance Registry System: 5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE(18336-75-9)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 18336-75-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE is used as a therapeutic agent for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is employed to improve impulse control and reduce hyperactivity in individuals with these conditions by modulating the levels of certain chemicals in the brain and nerves.
Used in ADHD Treatment:
5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE is used as a central nervous system stimulant to enhance focus, attention, and impulse control in patients with ADHD. It helps to alleviate symptoms such as inattention, hyperactivity, and impulsivity, thereby improving the quality of life and academic or work performance.
Used in Narcolepsy Treatment:
5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE is used as a wakefulness-promoting agent for the treatment of narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden episodes of muscle weakness triggered by strong emotions. It helps to increase alertness and reduce the frequency of sleep attacks in individuals with narcolepsy.
Used in Medical Research:
5-METHYL-3-PHENYL-4-ISOXAZOLECARBOHYDRAZIDE may also be used as a research compound in the development of new medications and therapies for various neurological and psychiatric disorders. Its mechanism of action and effects on brain chemistry make it a valuable tool for understanding the underlying causes of these conditions and identifying potential treatment options.

InChI:InChI=1/C11H11N3O2/c1-7-9(11(15)13-12)10(14-16-7)8-5-3-2-4-6-8/h2-6H,12H2,1H3,(H,13,15)

Upstream product

• 932-90-1 Benzaldoxime 
• 100-52-7 benzaldehyde 
• 1143-82-4 ethyl 5-methyl-3-phenylisoxazole-4-carboxylate 
• 1136-45-4 5-methyl-3-phenylisoxazol-4-carboxylic acid 
• 16883-16-2 5-methyl-3-phenylisoxazole-4-carbonyl chloride 

Downstream Products

• 18336-85-1 5-methyl-3-phenyl-isoxazole-4-carboxylic acid furfurylidenehydrazide 
• 68055-45-8 1-(3'-Phenyl-5'-methyl-4'-isoxazolyl)-2-furoylhydrazine 
• 68055-50-5 1,2-Bis(3'-phenyl-5'-methyl-4'-isoxazolyl)hydrazine 
• 21011-53-0 5-(5-methyl-3-phenyl-isoxazol-4-yl)-3H-[1,3,4]oxadiazole-2-thione 
• 67565-85-9 5-methyl-3-phenyl-isoxazole-4-carboxylic acid (2-bromo-3-phenyl-allylidene)-hydrazide 
• 18336-86-2 5-methyl-3-phenyl-isoxazole-4-carboxylic acid (4,5-dibromo-furan-2-ylmethylene)-hydrazide 
• 68055-58-3 N'-(5-methyl-3-phenyl-isoxazole-4-carbonyl)-formohydrazonic acid ethyl ester 
• 67565-84-8 5-methyl-3-phenyl-isoxazole-4-carboxylic acid (3-phenyl-allylidene)-hydrazide 
• 18336-76-0 5-methyl-3-phenyl-isoxazole-4-carboxylic acid isopropylidenehydrazide 
• 18336-77-1 5-methyl-3-phenyl-isoxazole-4-carboxylic acid sec-butylidenehydrazide 
• 67565-82-6 5-methyl-3-phenyl-isoxazole-4-carboxylic acid (2,4-dihydroxy-benzylidene)-hydrazide 
• 21011-54-1 N'-(5-methyl-3-phenyl-isoxazole-4-carbonyl)-hydrazinecarbodithioic acid methyl ester 
• 21169-63-1 5-methyl-3-phenyl-isoxazole-4-carbonyl azide 
• 943129-99-5 5-[5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazol-2-yl]-1,3-dihydro-benzoimidazol-2-one 

Relevant articles and documents

A New Series of 1,3,4-Oxadiazole Linked Quinolinyl-Pyrazole/Isoxazole Derivatives: Synthesis and Biological Activity Evaluation

Abstract: A series of 1,3,4-oxadiazole bridged pyrazole/isoxazole bearing quinoline derivatives has been designed and synthesized by a clean and convenient method. Structures of the newly synthesized compounds have been confirmed by FTIR, 1H and 13C NMR, and HRMS spectral data. The titled compounds have been evaluated for their molecular docking guided antimicrobial and anti-inflammatory activity. One of 1,3,4-oxadiazole bridged quinolinyl-pyrazole derivatives has interacted efficiently with E. Coli protein (PDB file: 1KZN), and has been characterized by good antimicrobial activity against the majority of the tested pathogens. Another product has exhibited excellent anti-inflammatory activity.

N-Amino-1,8-Naphthalimide is a Regenerated Protecting Group for Selective Synthesis of Mono-N-Substituted Hydrazines and Hydrazides

A new route to synthesis of various mono-N-substituted hydrazines and hydrazides by involving in a new C?N bond formation by using N-amino-1,8-naphthalimide as a regenerated precursor was invented. Aniline and phenylhydrazines are reproduced upon reacting these individually with 1,8-naphthalic anhydride followed by hydrazinolysis. The practicality and simplicity of this C?N dihalo alkanes; developed a synthon for bond formation protocol was exemplified to various hydrazines and hydrazides. N-amino-1,8-naphthalimide is suitable synthon for transformation for selective formation of mono-substituted hydrazine and hydrazide derivatives. Those are selective mono-amidation of hydrazine with acid halides; mono-N-substituted hydrazones from aldehydes; synthesis of N-aminoazacycloalkanes from acetohydrazide scaffold and inserted to hydroxy derivatives; distinct synthesis of N,N-dibenzylhydrazines and N-benzylhydrazines from benzyl halides; synthesis of N-amino-amino acids from α-halo esters. Ecofriendly reagent N-amino-1,8-naphthalimide was regenerated with good yields by the hydrazinolysis in all procedures.

ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES

The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula (I) wherein R1 is hydrogen, halogen, aryl, heterocyclyl, heteroaryl, cyano, lower alkyl, -(CH2)n-cycloalkyl, -(CH2)n/